• Consensus Rating: Buy
  • Consensus Price Target: $271.26
  • Forecasted Upside: 2.84 %
  • Number of Analysts: 26
  • Breakdown:
  • 0 Sell Ratings
  • 10 Hold Ratings
  • 16 Buy Ratings
  • 0 Strong Buy Ratings
$263.78
▼ -3.22 (-1.21%)

This chart shows the closing price for BIIB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Biogen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BIIB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BIIB

Analyst Price Target is $271.26
▲ +2.84% Upside Potential
This price target is based on 26 analysts offering 12 month price targets for Biogen in the last 3 months. The average price target is $271.26, with a high forecast of $360.00 and a low forecast of $190.00. The average price target represents a 2.84% upside from the last price of $263.78.

This chart shows the closing price for BIIB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 26 polled investment analysts is to buy stock in Biogen. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 17 buy ratings
  • 13 hold ratings
  • 0 sell ratings
4/10/2021
  • 0 strong buy ratings
  • 16 buy ratings
  • 12 hold ratings
  • 0 sell ratings
7/9/2021
  • 0 strong buy ratings
  • 18 buy ratings
  • 11 hold ratings
  • 0 sell ratings
10/7/2021
  • 0 strong buy ratings
  • 18 buy ratings
  • 12 hold ratings
  • 0 sell ratings
1/5/2022
  • 0 strong buy ratings
  • 19 buy ratings
  • 13 hold ratings
  • 0 sell ratings
4/5/2022
  • 0 strong buy ratings
  • 17 buy ratings
  • 10 hold ratings
  • 0 sell ratings
7/4/2022
  • 0 strong buy ratings
  • 17 buy ratings
  • 10 hold ratings
  • 0 sell ratings
9/2/2022
  • 0 strong buy ratings
  • 16 buy ratings
  • 10 hold ratings
  • 0 sell ratings
10/2/2022

Latest Recommendations

  • 0 strong buy ratings
  • 16 buy ratings
  • 10 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/30/2022JPMorgan Chase & Co.Boost Target$221.00 ➝ $275.00Low
9/29/2022OppenheimerBoost Target$230.00 ➝ $300.00Low
9/28/2022Piper SandlerBoost TargetNeutral$200.00 ➝ $280.00Low
9/28/2022Royal Bank of CanadaBoost Target$251.00 ➝ $321.00Low
9/28/2022Wells Fargo & CompanyBoost TargetOverweight$265.00 ➝ $350.00Low
9/28/2022WedbushBoost TargetNeutral$183.00 ➝ $217.00Low
9/28/2022Robert W. BairdUpgradeNeutral ➝ Outperform$224.00 ➝ $340.00Low
9/28/2022BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$217.00 ➝ $360.00Low
9/28/2022MizuhoUpgradeNeutral ➝ Buy$207.00 ➝ $270.00Low
9/22/2022Truist FinancialLower TargetBuy$270.00 ➝ $265.00Low
9/20/2022Jefferies Financial GroupReiterated RatingBuy ➝ Buy$300.00Low
9/12/2022Stifel NicolausLower TargetHold$230.00 ➝ $223.00Low
8/2/2022Robert W. BairdReiterated RatingNeutral ➝ Neutral$224.00Low
7/22/2022UBS GroupLower Target$238.00Low
7/22/2022GuggenheimLower Target$190.00Low
7/22/2022Robert W. BairdReiterated RatingNeutral ➝ Neutral$224.00Low
7/21/2022CowenLower TargetOutperform$285.00 ➝ $270.00Low
7/21/2022Truist FinancialLower TargetBuy$320.00 ➝ $270.00Low
7/21/2022Needham & Company LLCLower TargetBuy$262.00 ➝ $250.00Low
7/21/2022CowenLower Target$285.00 ➝ $270.00Low
7/21/2022BarclaysLower TargetEqual Weight$210.00 ➝ $200.00Low
7/20/2022Royal Bank of CanadaLower Target$264.00 ➝ $259.00Low
7/18/2022OppenheimerBoost TargetOutperform$225.00 ➝ $230.00Low
5/4/2022OppenheimerLower Target$240.00 ➝ $225.00Medium
5/4/2022BarclaysLower Target$219.00 ➝ $210.00Medium
4/28/2022WedbushReiterated RatingNeutralMedium
4/21/2022SVB LeerinkLower TargetOutperform$300.00 ➝ $270.00Medium
4/18/2022Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$235.00 ➝ $265.00Medium
4/12/2022Morgan StanleyLower TargetOverweight$330.00 ➝ $283.00High
4/12/2022BarclaysLower TargetEqual Weight$235.00 ➝ $219.00Medium
4/8/2022Needham & Company LLCLower TargetBuy$290.00 ➝ $262.00High
4/8/2022OppenheimerLower TargetOutperform$285.00 ➝ $240.00High
3/28/2022Bank of AmericaLower TargetNeutral$230.00 ➝ $225.00Low
3/25/2022OppenheimerReiterated RatingOutperform ➝ Outperform$285.00Low
3/8/2022Stifel NicolausDowngradeBuy ➝ Hold$304.00 ➝ $223.00Medium
3/3/2022Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$227.00 ➝ $248.00Low
2/7/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$335.00 ➝ $305.00Medium
2/7/2022Canaccord Genuity GroupLower TargetBuy$335.00 ➝ $305.00Low
2/4/2022CowenLower TargetOutperform$375.00 ➝ $285.00High
2/4/2022Wolfe ResearchLower TargetPeer Perform$244.00 ➝ $217.00High
2/4/2022Bank of AmericaLower TargetNeutral$245.00 ➝ $230.00High
2/4/2022Needham & Company LLCLower TargetBuy$292.00 ➝ $290.00High
2/4/2022Royal Bank of CanadaBoost TargetSector Perform$225.00 ➝ $227.00High
2/4/2022WedbushLower TargetNeutral$195.00 ➝ $185.00High
2/4/2022Wells Fargo & CompanyLower TargetEqual Weight$284.00 ➝ $235.00High
2/4/2022Morgan StanleyLower TargetOverweight$360.00 ➝ $330.00High
2/4/2022OppenheimerLower TargetOutperform$350.00 ➝ $285.00High
2/4/2022BarclaysLower TargetEqual Weight$244.00 ➝ $235.00High
2/4/2022Robert W. BairdLower TargetNeutral$258.00 ➝ $224.00High
2/4/2022BMO Capital MarketsDowngradeOutperform ➝ Market Perform$260.00 ➝ $238.00Medium
2/3/2022Stifel NicolausLower Target$344.00 ➝ $304.00Low
1/24/2022SVB LeerinkLower TargetOutperform$325.00 ➝ $300.00High
1/20/2022BarclaysLower TargetEqual Weight$280.00 ➝ $244.00Medium
1/18/2022Morgan StanleyLower TargetOverweight$363.00 ➝ $360.00Low
1/18/2022HC WainwrightLower TargetBuy$452.00 ➝ $270.00Low
1/14/2022Bank of AmericaLower TargetNeutral ➝ Neutral$275.00 ➝ $245.00Low
1/13/2022GuggenheimDowngradeBuy ➝ Neutral$290.00 ➝ $202.00High
1/12/2022MizuhoLower TargetNeutral$270.00 ➝ $207.00High
1/12/2022WedbushLower TargetNeutral$249.00 ➝ $195.00High
1/12/2022Piper SandlerDowngradeOverweight ➝ Neutral$362.00 ➝ $216.00High
1/11/2022Needham & Company LLCLower TargetBuy$386.00 ➝ $328.00High
1/10/2022Truist FinancialLower TargetBuy ➝ Buy$502.00 ➝ $343.00High
1/6/2022Morgan StanleyLower TargetOverweight$440.00 ➝ $363.00Low
1/3/2022Robert W. BairdReiterated RatingNeutral ➝ Neutral$258.00Low
1/3/2022UBS GroupLower Target$390.00 ➝ $335.00Low
12/30/2021Wells Fargo & CompanyBoost Target$250.00 ➝ $284.00Low
12/23/2021Bank of AmericaLower TargetNeutral$295.00 ➝ $275.00Low
12/22/2021Truist FinancialLower TargetReduce ➝ Buy$502.00Low
12/22/2021OppenheimerLower TargetOutperform$390.00 ➝ $350.00Low
12/21/2021JPMorgan Chase & Co.Lower TargetNeutral$324.00 ➝ $276.00Low
12/21/2021Robert W. BairdLower TargetNeutral$296.00 ➝ $258.00Medium
12/20/2021SVB LeerinkLower TargetOutperform$450.00 ➝ $325.00High
12/8/2021Wells Fargo & CompanyInitiated CoverageEqual Weight$250.00Low
12/6/2021The Goldman Sachs GroupInitiated CoverageNeutral$271.00Low
11/19/2021Royal Bank of CanadaLower TargetSector Perform$295.00 ➝ $277.00Low
11/18/2021BMO Capital MarketsInitiated CoverageOutperform$315.00Low
10/28/2021Cantor FitzgeraldLower TargetNeutral$316.00 ➝ $259.00Medium
10/26/2021MizuhoLower TargetNeutral$300.00 ➝ $270.00Low
10/21/2021HC WainwrightReiterated RatingBuy$453.00Low
10/21/2021Truist FinancialLower TargetBuy$647.00 ➝ $502.00Low
10/21/2021Morgan StanleyLower TargetOverweight$447.00 ➝ $440.00Medium
10/21/2021CowenBoost TargetOutperform$375.00 ➝ $450.00Medium
10/21/2021OppenheimerDowngradeOverweight$450.00 ➝ $390.00Medium
10/21/2021Royal Bank of CanadaLower TargetSector Perform$325.00 ➝ $295.00Medium
10/20/2021Piper SandlerLower TargetOverweight$460.00 ➝ $390.00Medium
10/19/2021Needham & Company LLCInitiated CoverageBuy$400.00 ➝ $399.00High
10/18/2021Jefferies Financial GroupReiterated RatingBuyHigh
10/15/2021Stifel NicolausLower TargetBuy$430.00 ➝ $344.00Low
10/15/2021Cantor FitzgeraldLower TargetNeutral$427.00 ➝ $327.00High
10/12/2021Morgan StanleyLower TargetOverweight$455.00 ➝ $447.00Low
10/8/2021Jefferies Financial GroupLower TargetBuy$500.00 ➝ $400.00Low
10/8/2021BarclaysLower TargetEqual Weight$395.00 ➝ $290.00Low
10/5/2021HC WainwrightReiterated RatingBuy$452.00Medium
10/5/2021SVB LeerinkReiterated RatingBuyLow
9/29/2021Royal Bank of CanadaLower TargetSector Perform$341.00 ➝ $326.00Low
9/24/2021Robert W. BairdInitiated CoverageHold$296.00Low
9/23/2021MizuhoInitiated CoverageHold$300.00Low
9/23/2021HC WainwrightReiterated RatingBuy$452.00Low
9/22/2021Needham & Company LLCInitiated CoverageBuy$400.00Low
9/16/2021UBS GroupBoost TargetPositive ➝ Buy$442.00 ➝ $475.00Low
9/15/2021Bank of AmericaLower TargetNeutral$400.00 ➝ $360.00Low
8/2/2021MizuhoBoost TargetNeutral$244.00 ➝ $300.00Medium
7/27/2021Cantor FitzgeraldReiterated RatingNeutral$435.00 ➝ $327.51Low
7/23/2021Morgan StanleyBoost TargetOverweight$453.00 ➝ $455.00Low
7/23/2021Royal Bank of CanadaLower TargetSector Perform$361.00 ➝ $341.00Low
7/22/2021Stifel NicolausLower TargetAverage ➝ Buy$443.00 ➝ $430.00Low
7/19/2021Evercore ISISet TargetBuy$324.62Low
7/16/2021Morgan StanleyLower TargetOverweight$455.00 ➝ $453.00Low
7/11/2021Robert W. BairdSet TargetHold$358.16Medium
6/28/2021Royal Bank of CanadaLower TargetSector Perform$400.00 ➝ $354.00Low
6/18/2021Piper SandlerUpgradeNeutral ➝ Overweight$384.00 ➝ $450.00Low
6/15/2021Bank of AmericaReiterated RatingBuy$415.00Low
6/14/2021The Goldman Sachs GroupBoost TargetAverage ➝ Neutral$246.00 ➝ $436.00Low
6/11/2021Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$500.00Medium
6/10/2021UBS GroupUpgradeNeutral ➝ Buy$463.00Low
6/10/2021SVB LeerinkBoost TargetOutperform$380.00 ➝ $475.00Medium
6/8/2021William BlairUpgradeMarket Perform ➝ OutperformHigh
6/8/2021Royal Bank of CanadaBoost TargetSector Perform$259.00 ➝ $400.00High
6/8/2021Jefferies Financial GroupBoost TargetBuy$450.00 ➝ $500.00Medium
6/8/2021Morgan StanleyBoost TargetOverweight$343.00 ➝ $455.00Medium
6/8/2021BarclaysBoost TargetEqual Weight$265.00 ➝ $395.00Medium
6/8/2021HC WainwrightBoost TargetBuy$305.00 ➝ $452.00Medium
6/8/2021CitigroupUpgradeSell ➝ NeutralMedium
6/8/2021Atlantic SecuritiesUpgradeUnderweight ➝ Neutral$415.00Low
6/7/2021Robert W. BairdUpgradeUnderperform ➝ Neutral$216.00 ➝ $382.00Medium
6/7/2021Raymond JamesUpgradeUnderperform ➝ Market PerformMedium
6/7/2021CowenUpgradeMarket Perform ➝ Outperform$225.00 ➝ $450.00High
6/7/2021Bank of AmericaUpgradeUnderperform ➝ Neutral$235.00 ➝ $400.00High
5/18/2021OppenheimerBoost TargetOutperform$300.00 ➝ $325.00Low
4/23/2021HC WainwrightReiterated RatingBuyLow
4/19/2021Morgan StanleyLower TargetOverweight$351.00 ➝ $343.00Low
4/12/2021WedbushBoost TargetNeutral$236.00 ➝ $245.00Medium
2/17/2021Cantor FitzgeraldLower TargetNeutral$278.00 ➝ $268.00Low
2/5/2021DZ BankDowngradeBuy ➝ Hold$264.00Low
2/4/2021Credit Suisse GroupLower TargetOutperform$388.00 ➝ $350.00Medium
2/4/2021SVB LeerinkLower TargetPositive ➝ Outperform$430.00 ➝ $380.00Medium
2/4/2021Morgan StanleyLower TargetOverweight$352.00 ➝ $351.00Medium
2/4/2021HC WainwrightBoost TargetBuy$289.00 ➝ $305.00Medium
2/3/2021Piper SandlerLower TargetNeutral$265.00 ➝ $250.00Low
1/29/2021Stifel NicolausUpgradeHold ➝ Buy$258.00 ➝ $358.00High
1/19/2021Morgan StanleyLower TargetOverweight$357.00 ➝ $352.00High
12/1/2020William BlairReiterated RatingMarket PerformLow
12/1/2020Royal Bank of CanadaBoost TargetReduce ➝ Sector Perform$249.00 ➝ $256.00Low
11/19/2020Royal Bank of CanadaBoost TargetSector Perform$244.00 ➝ $249.00Low
11/10/2020Truist FinancialDowngradeBuy$310.00 ➝ $443.00Low
11/10/2020DZ BankUpgradeHold ➝ Buy$265.00Low
11/9/2020Royal Bank of CanadaLower TargetSector Perform$263.00 ➝ $244.00High
11/9/2020OppenheimerLower TargetOutperform$370.00 ➝ $330.00Medium
11/9/2020MizuhoLower TargetNeutral$282.00 ➝ $244.00Medium
11/9/2020HC WainwrightLower TargetBuy$318.00 ➝ $289.00High
11/9/2020CowenDowngradeOutperform ➝ Market Perform$275.00 ➝ $215.00High
11/9/2020Bank of AmericaDowngradeNeutral ➝ Underperform$240.00High
11/9/2020Atlantic SecuritiesDowngradeNeutral ➝ Underweight$175.00High
11/5/2020SVB LeerinkBoost TargetPositive ➝ Outperform$342.00 ➝ $402.00High
11/5/2020BMO Capital MarketsUpgradeMarket Perform$280.00 ➝ $343.00High
11/4/2020Bank of AmericaUpgradeUnderperform ➝ Neutral$230.00 ➝ $360.00High
11/4/2020Jefferies Financial GroupUpgradeHold ➝ Buy$450.00High
11/4/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$437.00 ➝ $390.00High
11/3/2020Cantor FitzgeraldLower Target$339.00 ➝ $278.00Low
10/28/2020UBS GroupInitiated CoverageNeutral$268.00High
10/27/2020MizuhoLower TargetNeutral$316.00 ➝ $282.00Low
10/22/2020HC WainwrightReiterated RatingBuyLow
10/22/2020OppenheimerLower TargetOutperform$360.00 ➝ $340.00Low
10/22/2020BarclaysLower TargetEqual Weight$275.00 ➝ $265.00Low
10/22/2020WedbushLower TargetNeutral$281.00 ➝ $244.00Low
10/22/2020Credit Suisse GroupLower TargetOutperform$359.00 ➝ $350.00Low
10/22/2020Morgan StanleyBoost TargetOverweight$355.00 ➝ $357.00Low
10/20/2020Piper SandlerLower TargetNeutral$270.00 ➝ $265.00Low
10/19/2020Royal Bank of CanadaLower TargetSector Perform$281.00 ➝ $268.00High
10/15/2020Bank of AmericaLower TargetUnderperform$255.00 ➝ $235.00Low
10/13/2020Morgan StanleyLower TargetOverweight$357.00 ➝ $355.00Low
9/18/2020Royal Bank of CanadaLower TargetSector Perform$284.00 ➝ $277.00High
9/13/2020JPMorgan Chase & Co.Reiterated RatingHoldHigh
8/19/2020SVB LeerinkLower TargetOutperform$350.00 ➝ $342.00Medium
8/7/2020Credit Suisse GroupUpgradeNeutral ➝ Outperform$270.00 ➝ $375.00Medium
8/7/2020OppenheimerBoost TargetOutperform$325.00 ➝ $360.00High
7/31/2020Raymond JamesReiterated RatingSellLow
7/29/2020JPMorgan Chase & Co.Reiterated RatingHold$279.00Low
7/27/2020Morgan StanleyUpgradeUnderweight ➝ Overweight$263.00 ➝ $357.00High
7/23/2020BMO Capital MarketsLower TargetMarket Perform$317.00 ➝ $280.00Low
7/22/2020MizuhoReiterated RatingHold$316.00Low
7/22/2020Wells Fargo & CompanyBoost TargetEqual Weight$311.00 ➝ $324.00Low
7/22/2020Stifel NicolausLower TargetPositive ➝ Hold$294.00 ➝ $284.00Medium
7/16/2020OppenheimerReiterated RatingBuy$325.00Low
7/15/2020Morgan StanleyLower TargetUnderweight$301.00 ➝ $263.00Low
7/13/2020The Goldman Sachs GroupLower TargetNeutral$300.00 ➝ $257.00Medium
7/10/2020William BlairReiterated RatingHoldLow
7/8/2020SunTrust BanksReiterated RatingBuy$330.00Low
7/8/2020GuggenheimReiterated RatingBuy$390.00Low
7/6/2020Royal Bank of CanadaReiterated RatingHold$276.00Low
6/25/2020Credit Suisse GroupReiterated RatingHold$270.00Low
6/22/2020Royal Bank of CanadaLower TargetSector Perform$303.00 ➝ $273.00Low
6/22/2020BarclaysDowngradeOverweight ➝ Equal Weight$370.00 ➝ $280.00Low
6/19/2020JPMorgan Chase & Co.Reiterated RatingHoldMedium
6/19/2020William BlairReiterated RatingHoldHigh
6/19/2020Robert W. BairdLower TargetUnderperform$290.00 ➝ $228.00High
6/19/2020Credit Suisse GroupLower TargetNeutral$310.00 ➝ $270.00High
6/19/2020Piper SandlerLower TargetNeutral$307.00 ➝ $260.00High
6/18/2020MizuhoReiterated RatingHold$316.00High
6/9/2020Sanford C. BernsteinDowngradeOutperform ➝ Market Perform$360.00 ➝ $297.00Medium
5/28/2020Morgan StanleyReiterated RatingSell$301.00Low
5/1/2020Cantor FitzgeraldReiterated RatingNeutral$361.00 ➝ $308.00Low
4/30/2020Royal Bank of CanadaReiterated RatingHold$310.00High
4/24/2020William BlairReiterated RatingHoldHigh
4/23/2020Morgan StanleyLower TargetUnderweight$302.00 ➝ $301.00Medium
4/23/2020SunTrust BanksLower TargetBuy$360.00 ➝ $330.00Medium
4/23/2020OppenheimerLower TargetOutperform$390.00 ➝ $365.00Low
4/23/2020Credit Suisse GroupLower TargetNeutral$344.00 ➝ $310.00Low
4/23/2020BarclaysLower TargetOverweight$389.00 ➝ $370.00Low
4/23/2020Royal Bank of CanadaLower TargetSector Perform$325.00 ➝ $310.00Low
4/23/2020CitigroupDowngradeNeutral ➝ Sell$365.00 ➝ $240.00Low
4/22/2020Raymond JamesDowngradeMarket Perform ➝ UnderperformMedium
4/22/2020Stifel NicolausLower TargetHold$296.00 ➝ $294.00High
4/22/2020WedbushLower TargetNeutral$306.00 ➝ $295.00High
4/22/2020MizuhoReiterated RatingHold$316.00High
4/8/2020SVB LeerinkReiterated RatingOutperformHigh
3/31/2020Wolfe ResearchInitiated CoverageMarket Perform$331.00Low
3/18/2020Royal Bank of CanadaReiterated RatingHold$335.00High
2/27/2020BarclaysInitiated CoverageOverweight$389.00High
2/25/2020MizuhoBoost TargetNeutral$300.00 ➝ $316.00Medium
2/11/2020William BlairReiterated RatingMarket PerformLow
2/7/2020OppenheimerBoost Target$338.00 ➝ $390.00Low
2/7/2020Nomura SecuritiesBoost TargetBuy$320.00 ➝ $392.00Low
2/6/2020BMO Capital MarketsReiterated RatingMarket Perform$317.00Low
2/6/2020Morgan StanleyBoost TargetUnderweight$261.00 ➝ $302.00Low
2/6/2020SVB LeerinkBoost TargetOutperform ➝ Positive$350.00 ➝ $410.00Medium
2/6/2020Credit Suisse GroupBoost TargetNeutral$300.00 ➝ $330.00Medium
2/6/2020Wells Fargo & CompanyBoost TargetEqual Weight$286.00 ➝ $311.00Low
2/6/2020JPMorgan Chase & Co.Reiterated RatingHoldMedium
2/6/2020HC WainwrightReiterated RatingBuy$335.00Medium
2/6/2020Cantor FitzgeraldBoost TargetNeutral$315.00 ➝ $361.00Medium
2/5/2020MizuhoReiterated RatingHold$300.00Low
2/5/2020Robert W. BairdBoost TargetUnderperform ➝ Underperform$250.00 ➝ $290.00Low
2/3/2020SVB LeerinkBoost TargetOutperform$350.00 ➝ $410.00High
2/3/2020SunTrust BanksBoost TargetBuy$337.00 ➝ $360.00Medium
2/2/2020Credit Suisse GroupReiterated RatingOverweight ➝ Hold$330.00 ➝ $300.00Low
1/31/2020Morgan StanleyLower TargetUnderweight$270.00 ➝ $261.00Low
1/31/2020Cantor FitzgeraldBoost TargetPositive ➝ Neutral$300.00 ➝ $315.00High
1/30/2020WedbushReiterated RatingNeutralHigh
1/30/2020JPMorgan Chase & Co.Reiterated RatingHoldLow
1/27/2020Royal Bank of CanadaReiterated RatingHold$285.00Low
1/23/2020Credit Suisse GroupReiterated RatingHold$300.00Low
1/23/2020Robert W. BairdReiterated RatingSell$250.00Low
1/17/2020Morgan StanleyBoost TargetUnderweight$262.00 ➝ $270.00Low
1/2/2020CowenReiterated RatingBuy$325.00Low
12/13/2019Credit Suisse GroupUpgradeUnderperform ➝ Neutral$260.00 ➝ $300.00Medium
12/6/2019Raymond JamesReiterated RatingHoldLow
12/6/2019HC WainwrightReiterated RatingBuy$335.00Low
12/2/2019Robert W. BairdDowngradeNeutral ➝ Underperform$250.00Low
11/18/2019Royal Bank of CanadaReiterated RatingHold$267.00Medium
11/12/2019SunTrust BanksInitiated CoverageBuy$337.00Medium
11/1/2019Standpoint ResearchDowngradeBuy ➝ HoldLow
10/29/2019Sanford C. BernsteinUpgradeMarket Perform ➝ OutperformLow
10/25/2019William BlairReiterated RatingHoldLow
10/23/2019Bank of AmericaBoost TargetUnderperform$200.00 ➝ $235.00Low
10/23/2019Credit Suisse GroupBoost TargetUnderperform$203.00 ➝ $260.00Low
10/23/2019JPMorgan Chase & Co.Boost TargetNeutral$244.00 ➝ $260.00Low
10/23/2019BMO Capital MarketsBoost TargetMarket Perform$250.00 ➝ $297.00Medium
10/23/2019CowenBoost TargetOutperform$275.00 ➝ $325.00High
10/23/2019Morgan StanleyBoost TargetUnderweight$212.00 ➝ $262.00High
10/23/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$256.00 ➝ $350.00High
10/23/2019HC WainwrightBoost TargetBuy$300.00 ➝ $335.00High
10/23/2019GuggenheimUpgradeNeutral ➝ Buy$256.00 ➝ $365.00Medium
10/22/2019Jefferies Financial GroupBoost TargetHold$255.00 ➝ $310.00High
10/22/2019Stifel NicolausBoost TargetPositive ➝ Hold$236.00 ➝ $296.00High
10/22/2019UBS GroupBoost TargetOutperform ➝ Positive$280.00 ➝ $334.00High
10/22/2019CowenReiterated RatingOutperform$275.00 ➝ $325.00High
10/22/2019MizuhoReiterated RatingHold$235.00High
10/16/2019Bank of AmericaInitiated CoverageUnderperform$200.00Low
10/15/2019OppenheimerSet TargetBuy$280.00Low
10/11/2019Morgan StanleyBoost TargetUnderweight$211.00 ➝ $212.00Medium
9/23/2019JPMorgan Chase & Co.Set TargetHold$244.00Low
9/6/2019Royal Bank of CanadaSet TargetHold$242.00High
7/30/2019CowenReiterated RatingBuy$275.00Low
7/26/2019Piper Jaffray CompaniesReiterated RatingHoldN/A
7/25/2019MizuhoReiterated RatingHoldLow
6/28/2019Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$280.00 ➝ $250.00Medium
6/5/2019Standpoint ResearchUpgradeHold ➝ BuyLow
5/23/2019CitigroupReiterated RatingNeutral ➝ NeutralMedium
5/22/2019WedbushInitiated CoverageNeutral ➝ Neutral$231.00High
5/20/2019Credit Suisse GroupInitiated CoverageUnderperform$198.00Medium
5/9/2019BarclaysLower TargetEqual Weight$250.00 ➝ $245.00Medium
5/7/2019ArgusReiterated RatingHoldHigh
5/5/2019OppenheimerSet TargetBuy$290.00Medium
4/24/2019JPMorgan Chase & Co.Reiterated RatingHoldHigh
4/22/2019OppenheimerSet TargetBuy$290.00Low
4/22/2019MizuhoSet TargetHold$235.00Low
4/10/2019Raymond JamesInitiated CoverageMarket PerformLow
3/27/2019Cantor FitzgeraldReiterated RatingHold$250.00Low
3/25/2019Royal Bank of CanadaLower TargetSector Perform$236.00Low
3/25/2019HC WainwrightReiterated RatingBuy ➝ Buy$363.00 ➝ $300.00Low
3/22/2019GuggenheimSet TargetHold$236.00Medium
3/22/2019BarclaysReiterated RatingHold$250.00High
3/22/2019Nomura SecuritiesLower TargetBuy ➝ Buy$420.00 ➝ $320.00High
3/22/2019BMO Capital MarketsLower TargetMarket Perform$322.00 ➝ $250.00High
3/22/2019UBS GroupDowngradeBuy ➝ Neutral$395.00 ➝ $242.00High
3/22/2019Morgan StanleyDowngradeOverweight ➝ Underweight$401.00 ➝ $210.00High
3/21/2019CitigroupDowngradeBuy ➝ Neutral$470.00 ➝ $230.00High
3/21/2019Stifel NicolausReiterated RatingHold$346.00 ➝ $233.00High
3/21/2019Cantor FitzgeraldReiterated RatingOverweight ➝ Neutral$400.00High
3/21/2019The Goldman Sachs GroupDowngradeBuy ➝ NeutralHigh
3/21/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$244.00High
3/21/2019MizuhoDowngradeBuy ➝ Neutral$416.00 ➝ $235.00High
3/21/2019Bank of AmericaDowngradeBuy ➝ NeutralHigh
3/21/2019BTIG ResearchDowngradeBuy ➝ NeutralHigh
3/21/2019CowenLower TargetOutperform$400.00 ➝ $275.00High
3/21/2019GuggenheimReiterated RatingNeutral ➝ Neutral$325.00High
3/21/2019Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformHigh
3/21/2019Atlantic SecuritiesDowngradeOverweight ➝ NeutralHigh
3/21/2019William BlairDowngradeOutperform ➝ Market PerformHigh
3/21/2019Piper Jaffray CompaniesLower TargetMarket Perform ➝ Overweight$402.00 ➝ $280.00High
2/22/2019BMO Capital MarketsInitiated CoverageNeutral ➝ Market Perform$322.00Low
2/22/2019GuggenheimDowngradeBuy ➝ Neutral$410.00 ➝ $325.00Low
2/21/2019Stifel NicolausDowngradeBuy ➝ Hold$397.00 ➝ $346.00High
2/19/2019HC WainwrightReiterated RatingBuy$363.00Low
2/14/2019OppenheimerLower TargetOutperform$380.00 ➝ $375.00High
2/14/2019Royal Bank of CanadaReiterated RatingMarket PerformLow
2/12/2019Royal Bank of CanadaLower TargetSector Perform ➝ Fair Value$337.00 ➝ $318.00Low
1/30/2019CitigroupBoost TargetOutperform$372.00 ➝ $380.00High
1/30/2019SVB LeerinkBoost TargetMarket Perform$328.00 ➝ $341.00High
1/29/2019MizuhoSet TargetBuy$427.00High
1/29/2019Stifel NicolausBoost TargetBuy$392.00 ➝ $397.00Low
1/25/2019OppenheimerSet TargetBuy$372.00Medium
1/10/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
12/26/2018BTIG ResearchInitiated CoverageBuyHigh
12/20/2018BTIG ResearchInitiated CoverageBuy ➝ Buy$362.00High
12/19/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$394.00 ➝ $401.00Low
12/18/2018OppenheimerLower TargetOutperform$380.00 ➝ $372.00High
12/12/2018OppenheimerSet TargetBuy$380.00Low
12/12/2018Cantor FitzgeraldReiterated RatingBuy$400.00Low
11/26/2018Royal Bank of CanadaLower TargetSector Perform$338.00Low
10/28/2018OppenheimerSet TargetBuy$400.00 ➝ $380.00Low
10/24/2018JPMorgan Chase & Co.Lower TargetOverweight ➝ Buy$445.00 ➝ $436.00High
10/24/2018SVB LeerinkSet TargetHold$328.00 ➝ $340.00High
10/23/2018Raymond JamesSet TargetBuy$400.00Medium
10/23/2018MizuhoSet TargetBuy$427.00Low
10/19/2018Sanford C. BernsteinDowngradeOutperform ➝ Market Perform$373.00 ➝ $341.00High
10/19/2018OppenheimerSet TargetBuy$400.00High
10/8/2018CitigroupLower TargetBuy ➝ Buy$483.00 ➝ $470.00Low
10/3/2018Raymond JamesReiterated RatingBuyLow
10/1/2018Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$400.00Low
9/16/2018OppenheimerSet TargetBuy$400.00Medium
8/7/2018Stifel NicolausInitiated CoverageBuy$394.00High
7/31/2018MizuhoReiterated RatingBuy$427.00Low
7/29/2018OppenheimerSet TargetBuy$400.00Medium
7/26/2018CitigroupBoost TargetBuy ➝ Positive$483.00Medium
7/26/2018UBS GroupBoost TargetBuy ➝ Buy$354.00 ➝ $395.00Medium
7/25/2018Cantor FitzgeraldSet TargetHold$293.00Low
7/25/2018BarclaysBoost TargetEqual Weight ➝ Equal Weight$295.00 ➝ $320.00High
7/25/2018Robert W. BairdBoost TargetNeutral ➝ Neutral$323.00 ➝ $348.00High
7/25/2018SunTrust BanksBoost TargetBuy$321.00 ➝ $392.00High
7/25/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$366.00 ➝ $392.00High
7/24/2018GuggenheimReiterated RatingBuy$410.00High
7/24/2018CowenReiterated RatingBuy$408.00High
7/24/2018MizuhoReiterated RatingBuy$423.00High
7/24/2018JPMorgan Chase & Co.Boost TargetOverweight ➝ Hold$400.00 ➝ $445.00High
7/13/2018Morgan StanleyLower TargetOverweight$369.00 ➝ $366.00Low
7/11/2018Piper Jaffray CompaniesBoost TargetOverweight$365.00Low
7/10/2018Royal Bank of CanadaBoost TargetMarket Perform$349.00Medium
7/10/2018Robert W. BairdDowngradeOutperform ➝ Neutral$323.00Medium
7/9/2018UBS GroupDowngradeBuy ➝ HoldMedium
7/9/2018Jefferies Financial GroupBoost TargetPositive ➝ Hold$400.00Medium
7/9/2018HC WainwrightReiterated RatingBuyMedium
7/8/2018OppenheimerSet TargetBuy$375.00 ➝ $400.00Medium
7/6/2018Nomura SecuritiesReiterated RatingBuy$420.00High
7/6/2018JPMorgan Chase & Co.Reiterated RatingBuyHigh
7/6/2018CitigroupUpgradeNeutral ➝ Buy$371.00High
7/6/2018MizuhoSet TargetBuy$423.00High
6/29/2018MizuhoSet TargetBuy$423.00Medium
6/5/2018MizuhoSet TargetBuy$423.00Medium
5/3/2018MizuhoSet TargetBuy$423.00Low
5/2/2018CitigroupLower TargetNeutral ➝ Neutral$360.00 ➝ $290.00Low
4/26/2018Cantor FitzgeraldReiterated RatingNeutralMedium
4/25/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$365.00 ➝ $369.00Low
4/25/2018CitigroupReiterated RatingOutperform$400.00 ➝ $375.00High
4/25/2018SVB LeerinkSet TargetMarket Perform ➝ Hold$365.00 ➝ $325.00High
4/25/2018The Goldman Sachs GroupDowngradeConviction-Buy ➝ Buy$388.00 ➝ $262.15High
4/25/2018Robert W. BairdUpgradeNeutral ➝ OutperformHigh
4/24/2018OppenheimerSet TargetBuy$375.00High
4/24/2018Stifel NicolausSet TargetBuy$425.00High
4/24/2018GuggenheimSet TargetBuy$385.00High
4/24/2018Credit Suisse GroupSet TargetBuy$384.00High
4/24/2018SunTrust BanksSet TargetBuy$321.00High
4/24/2018Piper Jaffray CompaniesLower TargetOverweightHigh
4/24/2018CowenReiterated RatingBuy$408.00High
4/24/2018MizuhoSet TargetBuy$433.00High
4/24/2018Jefferies Financial GroupReiterated RatingHold$375.00 ➝ $300.00High
4/17/2018Credit Suisse GroupSet TargetBuy$384.00Medium
4/11/2018MizuhoSet TargetBuy$433.00Low
4/10/2018Sanford C. BernsteinSet TargetBuy$318.00Medium
4/5/2018BarclaysDowngradeOverweight ➝ Equal Weight$395.00 ➝ $295.00High
3/12/2018MizuhoSet TargetBuy$433.00Medium
3/12/2018Credit Suisse GroupReiterated RatingBuy$384.00Medium
3/2/2018GuggenheimSet TargetBuy$400.00Low
3/2/2018BMO Capital MarketsLower TargetOutperform ➝ Outperform$403.00 ➝ $393.00Low
2/16/2018ArgusDowngradeBuy ➝ HoldMedium
2/15/2018William BlairReiterated RatingBuyLow
2/8/2018JPMorgan Chase & Co.Reiterated RatingBuyHigh
2/7/2018Credit Suisse GroupUpgradeBuy$384.00High
2/4/2018MizuhoReiterated RatingBuy ➝ Buy$400.00 ➝ $433.00High
1/31/2018UBS GroupUpgradeNeutral ➝ Buy$352.59 ➝ $410.00Low
1/26/2018OppenheimerBoost TargetOutperform ➝ Buy$380.00 ➝ $400.00Low
1/26/2018Deutsche Bank AktiengesellschaftReiterated RatingBuy$373.00Low
1/26/2018Jefferies Financial GroupReiterated RatingHoldMedium
1/26/2018Royal Bank of CanadaBoost TargetSector Perform$347.00High
1/26/2018SunTrust BanksBoost TargetBuy$392.00High
1/26/2018HC WainwrightReiterated RatingBuy ➝ Buy$340.00 ➝ $363.00High
1/26/2018CowenReiterated RatingBuy$408.00High
1/25/2018BMO Capital MarketsReiterated RatingBuyHigh
1/25/2018Robert W. BairdReiterated RatingNeutral ➝ HoldHigh
1/25/2018JPMorgan Chase & Co.Set TargetBuy$378.00Medium
1/25/2018The Goldman Sachs GroupSet TargetBuy$390.00Medium
1/21/2018BarclaysReiterated RatingBuy$395.00Medium
1/18/2018MizuhoSet TargetBuy$400.00Low
1/16/2018CitigroupReiterated RatingOutperform$350.00 ➝ $380.00Medium
1/15/2018OppenheimerSet TargetBuy$380.00Medium
1/5/2018MizuhoSet TargetBuy$400.00High
1/2/2018Piper Jaffray CompaniesReiterated RatingBuyHigh
12/30/2017Nomura SecuritiesBoost TargetBuy$355.00 ➝ $420.00N/A
12/22/2017Nomura SecuritiesBoost TargetBuy ➝ Buy$355.00 ➝ $420.00Low
12/21/2017MizuhoSet TargetBuy$400.00Low
12/20/2017Credit Suisse GroupUpgradeNeutral ➝ Outperform$321.00 ➝ $385.00Low
12/18/2017Piper Jaffray CompaniesReiterated RatingBuy$390.00Low
12/5/2017Royal Bank of CanadaReiterated RatingHold$321.00Low
12/4/2017OppenheimerSet TargetBuy$350.00Low
11/28/2017OppenheimerSet TargetBuy$350.00Low
11/28/2017Sanford C. BernsteinSet TargetBuy$310.00 ➝ $318.00Medium
11/27/2017CowenReiterated RatingBuy$338.00Low
11/27/2017BMO Capital MarketsReiterated RatingBuy$385.00Low
11/27/2017JPMorgan Chase & Co.Set TargetBuy$378.00Medium
11/27/2017MizuhoSet TargetBuy$400.00Medium
11/22/2017OppenheimerReiterated RatingBuy$350.00N/A
11/13/2017MizuhoSet TargetBuy$400.00N/A
11/9/2017OppenheimerInitiated CoverageOutperform$350.00 ➝ $350.00N/A
11/6/2017BMO Capital MarketsBoost TargetOutperform$381.00 ➝ $386.00N/A
10/25/2017HC WainwrightReiterated RatingBuy$340.00N/A
10/25/2017Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$315.00 ➝ $313.00N/A
10/25/2017UBS GroupBoost TargetNeutral$285.00 ➝ $318.00N/A
10/25/2017BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$377.00N/A
10/24/2017SunTrust BanksReiterated RatingBuy$354.00N/A
10/24/2017Cantor FitzgeraldReiterated RatingHold$279.00N/A
10/23/2017GuggenheimInitiated CoverageBuy$402.00N/A
10/23/2017Piper Jaffray CompaniesReiterated RatingOverweight ➝ Overweight$390.00N/A
10/23/2017CitigroupDowngradeBuy ➝ NeutralN/A
10/18/2017Bank of AmericaBoost TargetBuy$358.00 ➝ $365.00N/A
10/17/2017Morgan StanleyReiterated RatingBuyN/A
10/17/2017MizuhoUpgradeNeutral ➝ Buy$319.00 ➝ $400.00N/A
10/17/2017Stifel NicolausUpgradeHold ➝ Buy$300.00 ➝ $415.00N/A
10/12/2017Stifel NicolausReiterated RatingHold$300.00N/A
10/5/2017Royal Bank of CanadaReiterated RatingHold$315.00N/A
10/5/2017Morgan StanleyUpgradeEqual Weight ➝ Overweight$311.00 ➝ $375.00N/A
(Data available from 10/3/2017 forward)

News Sentiment Rating

0.52 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 53 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
3/7/2022
  • 7 very positive mentions
  • 30 positive mentions
  • 6 negative mentions
  • 6 very negative mentions
4/6/2022
  • 5 very positive mentions
  • 44 positive mentions
  • 15 negative mentions
  • 3 very negative mentions
5/6/2022
  • 7 very positive mentions
  • 34 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
6/5/2022
  • 12 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
7/5/2022
  • 11 very positive mentions
  • 44 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
8/4/2022
  • 3 very positive mentions
  • 20 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
9/3/2022
  • 23 very positive mentions
  • 61 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
10/3/2022

Current Sentiment

  • 23 very positive mentions
  • 61 positive mentions
  • 7 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Biogen logo
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $263.78
Low: $260.68
High: $269.50

50 Day Range

MA: $211.47
Low: $194.69
High: $276.61

52 Week Range

Now: $263.78
Low: $187.16
High: $290.76

Volume

72,858 shs

Average Volume

1,249,224 shs

Market Capitalization

$38.28 billion

P/E Ratio

18.81

Dividend Yield

N/A

Beta

0.16

Frequently Asked Questions

What sell-side analysts currently cover shares of Biogen?

The following Wall Street analysts have issued reports on Biogen in the last twelve months: Bank of America Co., Barclays PLC, BMO Capital Markets, Canaccord Genuity Group Inc., Cantor Fitzgerald, Cowen Inc, Cowen Inc., Guggenheim, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, Truist Financial Co., UBS Group AG, Wedbush, Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for BIIB.

What is the current price target for Biogen?

27 Wall Street analysts have set twelve-month price targets for Biogen in the last year. Their average twelve-month price target is $271.26, suggesting a possible upside of 2.8%. BMO Capital Markets has the highest price target set, predicting BIIB will reach $360.00 in the next twelve months. Guggenheim has the lowest price target set, forecasting a price of $190.00 for Biogen in the next year.
View the latest price targets for BIIB.

What is the current consensus analyst rating for Biogen?

Biogen currently has 10 hold ratings and 16 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BIIB will outperform the market and that investors should add to their positions of Biogen.
View the latest ratings for BIIB.

What other companies compete with Biogen?

Other companies that are similar to Biogen include Seagen, Repligen, Gilead Sciences, Amgen and BioNTech. Learn More about companies similar to Biogen.

How do I contact Biogen's investor relations team?

Biogen's physical mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company's listed phone number is (617) 679-2000 and its investor relations email address is [email protected] The official website for Biogen is www.biogen.com. Learn More about contacing Biogen investor relations.